Form NT 10-K

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

COMMISSION FILE NUMBER 000-53078

 

NOTIFICATION OF LATE FILING

 

(Check One): [X] Form 10-K [  ] Form 20-F [  ] Form 11-K [  ] Form 10-Q [  ] Form 10-D [  ] Form N-SAR[  ] Form N-CSR

 

For Period Ended: December 31, 2020
[  ] Transition Report on Form 10-K
[  ] Transition Report on Form 20-F
[  ] Transition Report on Form 11-K
[  ] Transition Report on Form 10-Q
[  ] Transition Report on Form N-SAR
For the Transition Period Ended:________________

 

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:___________________________________

 

PART I - REGISTRANT INFORMATION

 

Bone Biologics Corporation

Full Name of Registrant
 
 
Former Name if Applicable
 

2 Burlington Woods Drive, Ste 100

Address of Principal Executive Office (Street and Number)
 

Burlington, MA 01803

City, State and Zip Code

 

 

 

 
 

 

PART II - RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

 

[X] (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
[X] (b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

     
(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III - NARRATIVE

 

State below in reasonable detail why Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

Bone Biologics Corporation (the “Company”) is unable to file its Annual Report on Form 10-K for the year ended December 31, 2020 (the “Annual Report”) within the prescribed time period without unreasonable effort and expense. The Company requires additional time (1) to complete its presentation of certain information in its financial statements and notes thereto that are contained in the Annual Report and (2) to compile supporting documentation for such information. The Company expects that the Annual Report will be filed no later than fifteen days after the prescribed filing date.

 

PART IV - OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

Jeffrey Frelick

  781  

552-4452

(Name)   (Area Code)   (Telephone Number)

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes [  ] [X] No Quarterly Reports on Form 10-Q for the periods ended March 31,2020, June 30, 2020 and September 30,2020

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
[  ] Yes [X] No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

  

  - 2 - 
 

  

Bone Biologics Corporation

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:March 30, 2021 By: /s/ JEFFREY FRELICK
    Jeffrey Frelick
    Chief Executive Officer

 

  - 3 -